Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan - PubMed (original) (raw)

. 2021 Nov 17;13(11):2294.

doi: 10.3390/v13112294.

You-Yu Lin 2, Chun-Jen Liu 2 3, Ya-Yun Lai 4, Shiou-Hwei Yeh 4 5, Hung-Chih Yang 3, Jia-Horng Kao 2 3, Shih-Jer Hsu 3 6, Yi-Hsiang Huang 7 8, Sheng-Shun Yang 9, Hsing-Tao Kuo 10, Pin-Nan Cheng 11, Ming-Lung Yu 12, Pei-Jer Chen 2 3

Affiliations

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan

Chun-Ming Hong et al. Viruses. 2021.

Abstract

About 4% of the population in Taiwan are seropositive for anti-HCV Ab and 70% with HCV RNA. To address this high chronic hepatitis C disease load, Taiwan National Health Insurance started reimbursing genotype-specific DAAs in 2017 and pangenotype DAAs in mid-2018. With a 97% SVR12 rate, there were still 2-3% of patients that failed to clear HCV. To understand the causes of DAA failure in Taiwan, we conducted a multi-center, clinical, and virologic study. A total of 147 DAA-failure patients were recruited, and we searched HCV NS3/4A, NS5A and NS5B for known resistance-associated substitutions (RASs) by population sequencing, and conducted whole genome sequencing (WGS) for those without known RASs. A total of 107 patients received genotype-specific DAAs while 40 had pangenotype DAAs. Clinically, the important cause of failure is poor adherence. Virologically, common RASs in genotype-specific DAAs were NS5A-L31, NS5A-Y93, and NS5B-C316, while common RASs in pangenotype DAAs were NS5A-L31, NS5A-A/Q/R30, and NS5A-Y93. Additionally, new amino acid changes were found by WGS. Finally, we identified 12 cases with inconsistent baseline and post-treatment HCV genotypes, which is suggestive of re-infection rather than treatment failure. Our study described the drug resistance profile for DAA failure in Taiwan, showing differences from other countries.

Keywords: Taiwan; chronic hepatitis C; direct-acting antiviral agent; resistance-associated substitution; treatment failure; whole genome sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1

Figure 1

Timeline of DAA reimbursement in National Health Insurance (NHI) in Taiwan.

Figure 2

Figure 2

Summary of (A) RASs in patients with genotype-specific DAA treatment and (B) cases with different baseline/post-treatment HCV genotype. “−”, negative.

Figure 3

Figure 3

Summary of (A) RASs in patients with pan-genotype DAA treatment and (B) cases with different baseline/post-treatment HCV genotype. “+”, positive; “−”, negative.

Figure 4

Figure 4

Comparison of RAS prevalence with other studies. (A) RAS prevalence compared to studies of Japan [23] and Spain [24]; (B) Detailed comparison of RAS prevalence for each DAA treatment to study results of Japan [23].

References

    1. WHO World Health Assembly, 69. Draft Global Health Sector Strategies: Viral Hepatitis, 2016–2021: Report by the Secretariat. 2016. [(accessed on 10 September 2021)]. Available online: https://apps.who.int/iris/handle/10665/252690.
    1. McEwan P., Ward T., Chen C.J., Lee M.H., Yang H.I., Kim R., Yuan Y. Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. Value Health Reg. Issues. 2014;3:5–11. doi: 10.1016/j.vhri.2013.08.001. - DOI - PubMed
    1. Kao J.H. Hepatitis C virus infection in Taiwan: Past, present and future. J. Formos Med. Assoc. 2016;115:65–66. doi: 10.1016/j.jfma.2015.06.012. - DOI - PubMed
    1. Yu M.L., Chuang W.L., Chen S.C., Dai C.Y., Hou C., Wang J.H., Chang W.Y. Changing prevalence of hepatitis C virus genotypes: Molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J. Med. Virol. 2001;65:58–65. doi: 10.1002/jmv.2001. - DOI - PubMed
    1. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment Web resource. Hepatology. 2014;59:318–327. doi: 10.1002/hep.26744. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources